Compare Campbell Soup Co. (CPB) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Cassava Sciences Inc — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.69B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Campbell Soup Co. is far larger — about 140.1× Cassava Sciences Inc's market cap, and Campbell Soup Co. pays a 6.96% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CPB | FLNA | |
|---|---|---|
Market Cap | $6.69B | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $4.64 |
52-Week Low | $20.00 | $0.87 |
Enterprise Value | $13.29B | -$34.93M |
Dividend Yield | 6.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $23.05, up 2.17% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings beat expectations in Q1 2026, while analyst sentiment remains cautious with only 3.45% buy ratings. The stock offers a 6.8% dividend yield, supported by positive cash flow from operations of $1.13B in 2025.
The outlook remains mixed with cost-saving initiatives and product innovation providing upside potential, but persistent margin challenges and high debt levels pose significant risks. Current valuation appears reasonable with P/E of 11.29, though weak analyst consensus suggests limited near-term catalyst for price appreciation beyond dividend income.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
